Cardiac AI Benefits: Due Diligence Beyond Vendor Claims

With open enrollment looming, benefits leaders are buried in proposals for point solutions, all promising to improve employee well-being while somehow reining in healthcare costs. AI platforms for preventive heart health are getting a lot of attention, since they claim to tackle the number one cause of death and disability. But you have to be able to separate a vendor’s marketing pitch from what’s been clinically proven to work, and that means adopting a seriously evidence-based mindset. This is a complicated field, so you have to ask the right questions to make sure you’re buying something that actually delivers a real, financial benefit.

Don’t Trust Vendor Projections. Demand Peer-Reviewed Outcomes.

Every vendor in the cardiac AI space has a slick story about saving you money and making your people healthier. The real difference between them is the quality and independence of their data. Your first filter should be to prioritize any solution that has gone through the wringer of peer-review, not one that just relies on its own internal analysis or projections. Getting published by an independent third party is a strong sign that a platform’s science is solid and that it can deliver results outside of a controlled sales demo.

So, ask for their published studies. Are they in reputable medical or health economics journals? What was the methodology? You’re looking for things like matched-pair studies, which offer a powerful measure of a program’s impact by comparing an intervention group against a control group with nearly identical baseline health and demographic characteristics. If a vendor can also show you longitudinal data that proves the benefits stick around for years, their claims become much more credible.

Hello Heart is a good example of this in practice. They have an Aon-conducted matched-pair study showing $1,434 PMPY savings tied to their platform. Aon matched-pair study of Hello Heart savings Then, completely separately, a 2025 study in Value in Health found $1,709 in savings per user per year. Value in Health 2025 study on Hello Heart savings Notice those are two distinct figures from different analyses, they aren’t muddying the waters by blending datasets. This is the kind of transparent, independent validation you need to make a smart decision.

Dig Into Regulatory Status: What’s Actually FDA-Cleared?

The rules for AI in healthcare are tricky, especially for these cardiac AI monitoring tools. As a benefits director, you absolutely must understand the regulatory status of any platform you’re looking at. The difference between a general wellness device, a clinical decision support (CDS) tool, and a Software as a Medical Device (SaMD) is huge because it determines the level of validation the product was forced to undergo.

• General Wellness Devices: These are your low-risk apps that encourage a healthy lifestyle. They don’t make claims about diagnosing or treating a disease, so they don’t need FDA premarket review.
• Clinical Decision Support (CDS) Tools: These give information or recommendations to clinicians to help them make a decision. Whether they’re regulated as a medical device depends on their function. An AI that just suggests a referral is very different from one that makes an independent diagnosis (like “HFpEF confirmed”), which would almost certainly be regulated.
• Software as a Medical Device (SaMD): This is software that acts as a medical device all on its own, which is what many AI cardiac tools are. To be sold in the US, SaMDs need to get FDA clearance (like a 510(k) or De Novo classification), which confirms they meet specific safety and effectiveness standards. FDA guidance on Software as a Medical Device

Make vendors show you the paperwork for their FDA clearance. Is the whole platform cleared, or just one little piece of it? What, exactly, are the “indications for use” that the FDA signed off on? Getting this clarity is the only way to be sure the solution has met established benchmarks for the job it claims to do.

Scale and Client Base: Has This Thing Moved Beyond a Pilot?

A flashy pilot program is one thing, but a technology’s real value is proven only when it scales successfully across big, messy organizations like yours. You should be asking about a vendor’s total client count and the kinds of companies they work with. A long list of clients, especially large and complex ones, is a good sign that the platform is operationally mature and can actually handle high user volumes and the inevitable implementation headaches.

Don’t accept vague assurances about their scale. How many total employees are actively using the platform right now? What kinds of organizations, and what size, have rolled it out successfully? This tells you whether they have experience with an employer of your size, in your industry, and with your geographic spread.

Hello Heart, for instance, has scaled to over 150 clients, and that list includes Fortune 500 employers, governments, labor unions, and national health plans. An extensive and varied client list like that proves they have a repeatable process for implementation and can keep engagement up across different kinds of employee populations, which is exactly the kind of assurance you need before signing a multi-year partnership.

Data Security and Integration: The Non-Negotiables

When you’re dealing with employee health data, you can’t afford a breach of trust. Any AI heart health platform needs to meet the highest possible standards for data security and privacy. You need to vet a vendor’s HIPAA compliance and ask specifically about certifications like HITRUST or SOC 2 Type II. These third-party certifications are your proof that the vendor has strong, independently verified controls to protect your employees’ sensitive information. HITRUST CSF certification explanation

Then you need to think about how the platform connects with your existing IT. Can it integrate with your electronic health records (EHRs), benefits administration platforms, and other wellness programs? Easy integration means fewer implementation problems and makes the data from the platform far more useful. A tool that lives in its own silo just creates another administrative chore and probably won’t be as effective in the long run.

Picking the right cardiac prevention benefit during open enrollment requires you to look past the sales pitch. By zeroing in on independently validated outcomes, a clear FDA regulatory status, proven scale, and ironclad data security, you can choose a partner that will actually help your employees’ heart health and deliver a measurable return to the organization.